site-industries-cosmetiques A cover of Industries Cosmétiques magazine
Discover all the innovations in perfumery and cosmetics.
Discover our special report: Save the People. Enjoy your direct access!
If you prefer the paper edition, please subscribe to our magazine
- advertising -

Serenibiome, a natural ingredient for skin prone to atopy

At the in-Cosmetics Global trade show, to be held in Paris from April 16 to 18, 2024, the Solabia group is unveiling its new ingredient for sensitive skin prone to atopy. Serenibiome is a patented double active based on flocculosin. This innovative glycolipid is obtained by biofermentation of Pseudozyma flocculosa and was inspired by this epiphytic fungus and the holobiont concept. 

Pseudozyma flocculosa is an epiphytic fungus that acts as a biocontrol agent by maintaining a healthy ecological niche for its host plant. Pseudozyma flocculosa has been identified on plant leaves infected by downy mildew, and is known to prevent the colonization of phytopathogens by releasing a specific extracellular glycolipid with powerful properties: flocculosin. Serenibiome's activity on an unbalanced microbiome and weakened skin is bioinspired by Pseudozyma flocculosa and its interactions with its plant host. Thanks to this powerful glycolipid, Serenibiome protects the skin holobiont.

A glycolipid from biotechnology

Backed by 30 years of expertise in biotechnology, the Solabia group has succeeded in developing an industrial process that mimics the natural production of flocculosin by Pseudozyma flocculosa. Serenibiome is the culmination of over eight years of R&D to develop an optimized bioguided fermentation process that induces the metabolic pathway of the fungus. 

This white biotechnology process meets high CSR standards thanks to water and energy management, a low-temperature process and low carbon emissions, and results in high-purity flocculosin, according to Sloabia. 

Serenibiome is a 100 % natural active ingredient, Cosmos-approved, preservative-free, eco-designed and easily biodegradable, suitable for sensitive skin prone to atopy.

Proven effectiveness

"Applied to skin health, Serenibiome has demonstrated exceptional and unmatched in vitro efficacy in bioselectively targeting the growth of Staphylococcus aureus without impacting the commensal population of Staphylococcus epidermidis "says Solabia.

S. aureus is the prevalent opportunistic bacterium implicated in the dysbiosis of the microbiome in atopy-prone skin, and recent studies have also shown its involvement in neurogenic inflammation, inducing itching and scratching by stimulating pruriceptors in sensory neurons. According to the company, preclinical studies have demonstrated the efficacy of Serenibiome on the drivers of the itch-scratch vicious circle, and this efficacy has been clinically confirmed by a metagenomic study with a correlated reduction in Scorad. 

"Serenibiome significantly improves the skin condition of children with mild to moderate atopic dermatitis after 28 days, calms neurogenic inflammation, helps limit pro-inflammatory signaling, enhances wellness neurotransmitters and supports the skin barrier."adds Solabia.

Photo: Iqbal Nuril Anwar / Pixabay

External resources
Website

Sponsored content

site-industries-cosmetiques A vibrant advertisement for Croda Beauty featuring a close-up of orange flowers with a blurred background effect and the text "Croda Beauty, intelligent science to improve life" now includes Phytess.

Phytessence™ Osmanthus, the first geo-skincare botanical extract by Croda Beauty

Discover how this innovative natural ingredient helps the skin to better face climate change, particularly the harmful effects of sun rays and heat.
site-industries-cosmetiques A concentrated individual in a lab coat examining a small jar containing a pink substance, a pioneering cosmetic innovation using natural ingredients in Brittany.

Cosmetics innovation comes naturally in Bretagne

In north-west France, Bretagne has always been a seawardlooking region with its 2,730km coastline - the longest in the country.

Related articles

Our last issue

Listen to us!

Newsletter

en_USEnglish